Indivior PLC (NASDAQ:INDV - Get Free Report) shares were up 3.8% during mid-day trading on Friday . The stock traded as high as $12.84 and last traded at $12.88. Approximately 414,700 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 1,034,635 shares. The stock had previously closed at $12.41.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler cut their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.
Check Out Our Latest Stock Analysis on Indivior
Indivior Trading Up 1.8%
The company has a market capitalization of $1.75 billion, a PE ratio of -36.23 and a beta of 0.98. The business's fifty day moving average is $10.55 and its two-hundred day moving average is $10.78.
Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.19. The firm had revenue of $266.00 million during the quarter, compared to analysts' expectations of $240.13 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. As a group, equities research analysts anticipate that Indivior PLC will post 1.22 EPS for the current year.
Hedge Funds Weigh In On Indivior
Hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Indivior in the fourth quarter worth approximately $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Indivior in the fourth quarter worth approximately $56,000. Lazard Asset Management LLC bought a new stake in Indivior in the 4th quarter worth approximately $57,000. Schaper Benz & Wise Investment Counsel Inc. WI bought a new stake in Indivior in the 1st quarter worth approximately $95,000. Finally, Cannon Global Investment Management LLC purchased a new stake in Indivior during the 1st quarter valued at $95,000. Institutional investors own 60.33% of the company's stock.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
